Index reshuffle puts Centene in the growth spotlight

Centene (CNC) has just been shifted across several Russell benchmarks, with the stock added to multiple growth indexes and removed from two defensive and value oriented indexes on June 27, 2026.

For investors, this kind of index reshuffle matters because it can influence which funds hold Centene and how the stock is perceived. Growth index inclusion often draws attention from benchmark tracking products, while removal from defensive and value indexes points to a different style classification.

• Added to the Russell 3000E Growth Benchmark
• Added to the Russell 1000 Growth Benchmark
• Added to the Russell 3000 Growth Benchmark
• Added to the Russell Midcap Growth Benchmark
• Dropped from the Russell 1000 Value Defensive Index
• Dropped from the Russell 1000 Defensive Index

This pattern of index changes places Centene within the growth style buckets on several widely followed benchmarks. For readers tracking style exposure in portfolios, it is a reminder that Centene may now appear more in growth allocations and less in value or defensive sleeves tied closely to Russell indexes.

Alongside Centene’s shift into growth indexes, the stock’s recent share price performance has been strong, with a 30 day share price return of 8.87%, a 90 day share price return of 91.69%, and a 1 year total shareholder return of 103.72%. However, the 5 year total shareholder return is down 7.69%, which gives investors a mix of short term momentum and a more modest longer term picture to weigh.

If this kind of style shift has you thinking about where growth could show up next in healthcare, it may be worth scanning the market for other opportunities linked to AI in the sector using the 40 healthcare AI stocks

Centene has been pushed firmly into the growth bucket and the share price has raced ahead, so the key question for you now is simple: is the stock still undervalued, or is the market already pricing in the recovery story?

Most Popular Narrative: 10% Overvalued

On the most followed narrative, Centene's fair value sits at about $61.83, which is below the last close of $67.86, putting a clear question mark over how much of the recovery story is already reflected in the price.

Analysts expect earnings to reach $2.7 billion (and earnings per share of $5.57) by about June 2029, up from $6.4 billion of losses today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $3.8 billion.

The fair value hinges on a sharp swing from losses to meaningful profits, steady revenue growth and a future earnings multiple that assumes Centene can sustain that profitability. Curious which revenue path, margin rebuild and P/E level this narrative is banking on to justify that $61.83 figure and the current premium in the share price? The full breakdown sets out each of those levers in detail.

Result: Fair Value of $61.83 (OVERVALUED)

However, the Centene narrative still faces pressure from potential policy shifts around Medicaid rates and the ongoing strain of high specialty drug and medical cost volatility.

Another View: Centene and the market’s fair ratio test

The narrative prices Centene as roughly 10% overvalued on a fair value of $61.83 versus a $67.86 share price, but the market is telling a different story when you look at sales. Centene trades on a P/S of 0.2x, far below the US Healthcare industry at 1.5x and an estimated fair ratio of 0.9x, which points to a wide valuation gap that could either signal caution on profitability or a potential opportunity in plain sight, depending on how you rate the earnings recovery story.

To see how that gap plays out in practice and what the numbers imply for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Centene clearly split between recovery optimism and policy risk concerns, take a moment to review the underlying data for yourself and decide where you stand by weighing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Centene?

If Centene has sharpened your appetite for opportunities, do not stop here; diversify your watchlist and keep fresh ideas coming by scanning different styles and risk profiles.

• Target potential bargains with solid fundamentals by reviewing the 44 high quality undervalued stocks that fit strict quality and valuation filters.
• Strengthen your portfolio’s foundation by focusing on companies highlighted in the solid balance sheet and fundamentals stocks screener (47 results) to assess financial resilience upfront.
• Aim to get ahead of the crowd by searching the screener containing 18 high quality undiscovered gems that may not yet be widely followed but already show robust underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.